Healthcare Provider Type and Switch to Biologics in Psoriasis: Evidence from Real-World Practice

BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
Paul S CalaraMarcus Schmitt-Egenolf

Abstract

Previous research indicates an uneven uptake of biologics in patients with moderate-to-severe psoriasis in Sweden. Therefore, it is essential to scrutinise variations in treatment patterns. The aim of this study was to evaluate the extent to which the uptake of biologics for psoriasis differs between types of healthcare provider. Three types of provider were identified within 52 units participating in the Swedish National Registry for Systemic Psoriasis Treatment (PsoReg): university hospitals, non-university hospitals and individual practices. Biologics-naïve patients (n = 3165) were included in analyses to investigate the probability of switch to biologics. The numbers of patients fulfilling the criteria for moderate-to-severe psoriasis [Psoriasis Area and Severity Index (PASI) ≥10 and Dermatology Life Quality Index (DLQI) ≥10] among patients who switched to biologics and patients who did not switch were reported. A logistic regression model was used to calculate how healthcare provider type influenced the probability of switch to biologics whilst adjusting for patient characteristics and disease severity. During registration, 16% of patients switched to biologics while 84% remained on conventional systemic treatment. In 7% o...Continue Reading

References

Jan 1, 1978·Dermatologica·T Fredriksson, U Pettersson
May 1, 1994·Clinical and Experimental Dermatology·A Y Finlay, G K Khan
Jun 26, 2001·Journal of the American Academy of Dermatology·B KirbyC E Griffiths
Oct 26, 2002·BMJ : British Medical Journal·John E Wennberg
Apr 17, 2004·The Journal of Investigative Dermatology·Francesca SampognaUNKNOWN IDI Multipurpose Psoriasis Research on Vital Experiences (IMPROVE) Investigators
Feb 15, 2005·Annals of the Rheumatic Diseases·R G B LangleyC E M Griffiths
Dec 1, 2006·Dermatology : International Journal for Clinical and Investigative Dermatology·Marcus Schmitt-Egenolf
Mar 8, 2007·Dermatology : International Journal for Clinical and Investigative Dermatology·Marcus Schmitt-Egenolf
Jul 31, 2009·The New England Journal of Medicine·Frank O NestleJonathan Barker
Oct 20, 2010·Scandinavian Journal of Rheumatology·M NeoviusUNKNOWN ARTIS Study Group
Jan 19, 2013·Dermatology : International Journal for Clinical and Investigative Dermatology·Jenny M NorlinMarcus Schmitt-Egenolf
Sep 24, 2013·Health Policy·Ashley N CoralloTherese A Stukel
Apr 16, 2014·Journal of the European Academy of Dermatology and Venereology : JEADV·R GyulaiL Kemény
Dec 1, 2015·The British Journal of Dermatology·K GealeM Schmitt-Egenolf
Dec 17, 2015·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Jenny M NorlinMarcus Schmitt-Egenolf

❮ Previous
Next ❯

Citations

Jan 18, 2017·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Paul S CalaraMarcus Schmitt-Egenolf
May 11, 2017·The Journal of Dermatological Treatment·Diana NorrisChris Baker
Jul 28, 2018·The Journal of Dermatological Treatment·Mina AminJashin J Wu
Nov 6, 2018·BMC Gastroenterology·Jörg MahlichRosarin Sruamsiri

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.